Ivanovo State Medical Academy

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Daniel V.T. Catenacci, Niall C. Tebbutt, André M. Murad et al. · The Lancet Oncology · 2017 · 338 citations · Full text

Advanced Met-positive Gastric, First-line Therapy, Gastrointestinal Oncology +7

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

David Cunningham, Niall C. Tebbutt, André M. Murad et al. · Journal of Clinical Oncology · 2015 · 143 citations

First-line Therapy, Esophageal Cancer, Immunology +17

Genome-wide Association Study Using Pooled DNA to Identify Candidate Markers Mediating Susceptibility to Postoperative Nausea and Vomiting

Piotr K. Janicki, Ryan J. Vealey, Jiabin Liu et al. · Anesthesiology · 2011 · 115 citations · Full text

The Influence of Rheumatoid Arthritis Disease Characteristics on Heart Failure

Elena Myasoedova, Cynthia S. Crowson, Paulo Nicola et al. · The Journal of Rheumatology · 2011 · 113 citations · Full text

Dispersion of TiO2 nanoparticles improves burn wound healing and tissue regeneration through specific interaction with blood serum proteins

Gulaim A. Seisenbaeva, Karin Fromell, Vasiliy V. Vinogradov et al. · Scientific Reports · 2017 · 109 citations · Full text